Adcock profit slides as talks to buy the drugmaker continue

Adcock Ingram Holdings' , the country’s largest supplier of hospital and critical-care products, ​net income for the six months through March dropped to R317.2-million ($32.3-million), from R335.3-million  a year earlier, the company said in a statement today. Diluted earnings per share excluding one-time items declined 5% to 187.9 cents.

Margins were “negatively impacted by the weak rand, competitive trading conditions, inflation-plus cost increases on raw materials and production inputs and the change in mix,” the South African maker of Panado painkillers and Corenza cold medicine said in the statement.


Adcock said on May 9 that it had received non-binding proposals that could lead to an offer for the whole company or a controlling stake, sending its shares to their highest in more than two years. The company is in “active discussions” with “a number of parties”, it said on May 31.


The interim dividend will be maintained at 86 cents per share, Adcock said. – Bloomberg

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Related stories


press releases

Loading latest Press Releases…

The best local and international journalism

handpicked and in your inbox every weekday